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Abstract
Background Electrical stimulation of the lower esopha-
geal sphincter (LES) has been shown to improve outcomes
in patients with gastroesophageal reflux disease (GERD) at
2 years. The aim of the study was to evaluate the safety and
efficacy of LES stimulation in the same cohort at 3 years.
Methods GERD patients with partial response to PPI,
with % 24-h esophageal pH\ 4.0 for[5 %, with hiatal
hernia \3 cm and with esophagitis BLA grade C were
treated with LES stimulation in an open-label 2-year trial.
All patients were on fixed stimulation parameter of 20 Hz,
220 ls, 5 mA delivered in twelve, 30-min sessions. After
completing the 2-year open-label study, they were offered
enrollment into a multicenter registry trial and were eval-
uated using GERD-HRQL, symptom diaries and pH testing
at their 3-year follow-up.
Results Fifteen patients completed their 3-year evaluation
[mean (SD) age = 56.1 (9.7) years; men = 8] on LES
stimulation. At 3 years, there was a significant improvement
in their median (IQR) GERD-HRQL on electrical stimula-
tion compared to both their on PPI [9 (6–10) vs. 1 (0–2),
p = 0.001] and off PPI [22 (21–24) vs. 1 (0–2), p\ 0.001].
Median 24-h distal esophageal acid exposure was signifi-
cantly reduced from [10.3 (7.5–11.6) % at baseline vs. 3
(1.9–4.5) %, p\ 0.001] at 3 years. Seventy-three % (11/15)
patients had normalized their distal esophageal acid expo-
sure at 3 years. Remaining four patients had improved their
distal esophageal acid exposure by 39–48 % from baseline.
All but four patients reported cessation of regular PPI use
([50 % of days with PPI use); three had normal esophageal
pH at 3 years. There were no unanticipated device- or
stimulation-related adverse events or untoward sensation
reported during the 2- to 3-year follow-up.
Conclusion LES-EST is safe and effective for treating
patients with GERD over long-term, 3-year duration. There
was a significant and sustained improvement in esophageal
acid exposure and reduction in GERD symptoms and PPI
use. Further, no new GI side effects or adverse events were
reported.
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Gastroesophageal reflux disease (GERD) is a chronic disease
with high global prevalence of up to 20 % [1]. GERD occurs
when a weak or dysfunctional lower esophageal sphincter
(LES) exposes the esophagus to acidic stomach contents,
resulting in bothersome symptomsofheartburn, regurgitation,
and chest pain and a significant impairment ofpatients’ quality
of life [2]. Acid damage can lead to stricture formation and
Barrett esophagus, which can eventually lead to esophageal
adenocarcinoma, one of the fastest rising cancers in the
Western world [3]. Excessive esophageal acid exposure is the
hallmark of this disease, and measurement of 24- to 48-h
esophageal acid exposure is the most robust gold-standard for
the diagnosis of GERD [4].
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and Other Interventional Techniques 
Current therapies aim to treat GERD by controlling or
eliminating esophageal acid exposure. Medications such as
proton pump inhibitors (PPI) minimize esophageal acid
exposure by blocking gastric acid secretion; however, due
to persistent LES dysfunction, reflux of non-acidic gastric
contents continues at comparable magnitude, resulting in
persistent symptoms in up to 40 % of patients [5].
Laparoscopic fundoplication for sphincter augmentation
controls reflux of all gastric contents; however, the
anatomical alteration at the level of the GE junction is
associated with multiple side effects, some debilitating,
that plague the procedure [6], as well as recurrence of
symptoms in a sizable number of patients [6, 7]. Concerns
about optimal outcomes in low-volume centers persist [8,
9]. Perhaps as a result, the number of fundoplication pro-
cedures performed has been declining [10].
An ideal antireflux procedure should result in long-
term control of esophageal acid exposure, without any
significant side effects or adverse events, thus improving
patients’ symptoms and quality of life without depen-
dence on daily medications [11]. We had previously
reported the results from our long-term, 2-year open-label
trial of LES stimulation in patient of GERD [12]. The
current report describes the results of stimulation therapy
after extension of the follow-up in the same cohort of
patients to 3 years.
Materials and methods
A Web-based international multicenter registry has been
established by EndoStim (The Hague, The Netherlands),
the manufacturer of the LES stimulation system, to allow
physicians to track the outcomes of their patients treated
with LES stimulation in their clinical practice outside of
clinical trials (NCT02441400). GERD patients with partial
response to PPI, with hiatal hernia B3 cm and with Bgrade
C esophagitis were enrolled in a single-center, open-label
trial of electrical stimulation of the LES using the
EndoStim LES stimulation system (Fig. 1). The system is
implanted laparoscopically and is programmed to deliver
intermittent stimulation to the LES. The details of the
open-label trial and the 2-year results have been previously
reported [12]. At the end of the 2-year follow-up, patients
were offered to participate in a registry trial to allow for a
follow-up of up to 5 years, to provide an assessment of
long-term clinical outcomes. The registry trial was
approved by the Institutional Review Board of Clinica
Indisa, Santiago, Chile. At their 3-year follow-up, patients
who enrolled in the registry trial were offered evaluation
using GERD-HRQL, and daily diary questionnaires, SF-12,
as well as esophageal pH testing to objectively measure
their esophageal acid exposure.
The effect of electrical stimulation of the LES on patient
symptoms was measured using GERD-HRQL (on PPI and
2 weeks off PPI at baseline and after 2 weeks off PPI
during follow-up), symptoms and medication use reported
in a daily diary, and general quality of life measured using
SF-12 (on PPI and 2 weeks off PPI at baseline and after
2 weeks off PPI during follow-up visits) using related
samples Wilcoxon signed-rank test was used for compari-
son. Change in % time distal esophageal pH was\4.0 was
assessed by comparing the results at baseline to the 3-year
follow-up. LES electrical stimulation therapy (EST) was
evaluated using related samples Wilcoxon signed-rank test.
A p value of\0.05 was considered statistically significant.
Results
Eighteen patients consented to enroll in the registry trial,
and 15 of those patients were available for evaluation at
3 years. The details of patient follow-up are presented in
Fig. 2, and the baseline characteristics of patients that
underwent 3-year evaluation are provided in Table 1.
There were no additional adverse events reported
between years 2 and 3 of follow-up. The details of adverse
events prior to 2 years have been previously reported [13]
and include two serious adverse events: acute non-cardiac
retrosternal chest pain and surgery for solitary thyroid
nodule, both deemed not related to device or procedure by
Fig. 1 LES stimulation system with electrodes implanted in the LES
and the pulse generator implanted in a subcutaneous pocket in the
anterior abdominal wall
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an independent data safety and monitoring board. There
were a total of 63 non-serious adverse events in the trial; 12
were classified as device/procedure related. Most device-/
procedure-related events were typical of a surgical implant
procedure (e.g., implant site pain, post-op nausea), mild–
moderate in severity and resolved with or without inter-
vention. There were no stimulation-related side effects or
sensation, and no events of dysphagia were reported.
The median distal esophageal acid exposure was sig-
nificantly improved at 3 years at 3 % (IQR 1.9–4.5) com-
pared to 10.1 % (7.8–13; p\ 0.001) in the whole cohort
and 10.3 % (4.0–7.8; p\ 0.001) in the matched cohort at
baseline (Fig. 3). Seventy-three % (11/15) reported nor-
malization (\4.0 % of 24 h) of their distal esophageal acid
exposure. The remaining four patients had 39–48 %
improvement in their distal esophageal acid exposures. The
median DeMeester score was significantly improved at
3 years from 36.9 (30.8–44.3) at baseline to 12.8 (7.2–18.8;
p = 0.0003).
Three patients underwent blinded turn-off of LES-EST
after their 18-month follow-up, and one patient had her
therapy accidentally turned-off by inadvertent use of a
magnet therapy for her arthritis at month 15. All four
patients demonstrated worsening of their distal esophageal
acid exposure at 2 years compared to their on-therapy at
12 months, though values improved, they did not return to
their baseline esophageal acid exposure even after
[3 months of cessation of LES-EST [12]. All these
patients had their stimulation turned back after their 2-year
visit, and three of these patients underwent esophageal pH
testing at 3 years. All three patients had significantly
improved or normalized their distal esophageal acid
exposure, suggesting a causal association between
improvement in esophageal acid exposure and LES stim-
ulation (Fig. 4).
The median composite GERD-HRQL scores were
significantly improved at 3 years at 1.0 (IQR 0–2.0)
compared to 23.5 (21–25; p\ 0.001) off PPI and 9.0
(6–10; p\ 0.001) on PPI, respectively, in the whole
cohort and 22 (21–24; p\ 0.001) off PPI and 9.0 (6–10;
p\ 0.001) on PPI, respectively, in the matched cohort at
baseline (Fig. 5). All patients reported clinical signifi-
cance ([ 50 % improvement) in their composite GERD-
HRQL score versus both their baseline off-PPI scores and
on-PPI scores. The SF-12 scores for both physical and
mental health improved numerically compared with
baseline on- and off-PPI scores, but did not reach statis-
tical significance. There was a significant reduction in
dependence on PPI medications. All patients at baseline
were on either single- or double-dose PPI for a median
duration of 6.0 years. Seventy-three % of patients were
free of PPI dependence at their 3-year follow-up (Fig. 6).
Three patients were using daily PPI, two had normal distal
esophageal acid exposure, and one was improved by
39 %, while one patients was using PPI 4X/week and had
normal distal esophageal acid exposure. All esophageal
pH measurements were off PPI.
All patients in the cohort had erosive esophagitis at
baseline. Twelve patients underwent endoscopy at their
3-year follow-up with 50 % (6/12) patients showing
improvement in their esophagitis by C1 grade, and 25 %
(3/12) patients each had stable grade A and worsening
Fig. 2 Patient follow-up chart
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(grade A to grade B) esophagitis. Two of the 3 patients that
had worsening esophagitis and all 3 patients with
stable esophagitis had normal esophageal acid exposure at
their 3-year evaluation. None of the patients had developed
Barrett esophagus at their 3-year follow-up on LES stim-
ulation therapy.
Discussion
This is the first report of sustained control of esophageal
acid exposure at 3 years with LES electrical stimulation in
patients with GERD, who were at least partially responsive
to PPI at baseline evaluation. Along with objective
improvement in GERD, there was sustained improvement
in GERD symptoms and GERD-related quality of life, and
elimination or reduction in need for daily PPI medications,
without any new adverse events.
Excessive esophageal acid exposure due to the failure of
the antireflux barrier is the hallmark of GERD. The current
gold-standard objective test to diagnose GERD is the
prolonged ambulatory esophageal pH-metry [14]. The total
time with esophageal pH\ 4 as recorded by a probe
placed 5 cm above the LES and the composite Johnson-
DeMeester score have the highest sensitivity and speci-
ficity in the diagnosis of GERD [4]. Control of esophageal
acid exposure is the most robust measure of effectiveness
of a GERD therapy, although pH testing has not been an
endpoint for most GERD therapy clinical trials. Our results
show a significant and sustained improvement in esopha-
geal acid exposure and Johnson-DeMeester composite
scores with LES stimulation at 3-year follow-up. Almost
Table 1 Baseline characteristics and relevant medical/GERD history
of patient treated per-protocol with LES stimulation and completing
their 3-year evaluation
Characteristic N Mean (SD)
Age (years) 15 56.1 (9.7)






Overweight (C25 and\30) 9
Obese (C30) 3
Patients using daily PPI 100 %
Duration of GERD symptoms
Mean (SD) [12.2 (9.1) years
Median (quartile) [10 (7.5–12.5) years
Duration of PPI use
Mean (SD) [5.9 (3.3) years
GERD-HRQL Total Score
On PPI
Median (IQR) 9 (6–10)
% not satisfied 80 %
Off PPI
Median (IQR) 22 (20.5–24)
% not satisfied 94 %
Total % pH time\4, Median (IQR) 10.3 (7.5–11.6)
DeMeester Score, Median (IQR) 36.9 (30.8–44.3)
Esophagitis (%) grade A/B/C 60/33.3/6.7
Hiatal hernia (%) none/\2 cm/C2 cm 93.3/0/6.7
SD = standard deviation, IQR interquartile range
Fig. 3 Sustained improvement in the distal esophageal acid exposure
on LES stimulation at 3-year follow-up. Data: median, IQR. 73 %
reported normalization (\4.0 % of 24 h) in their distal esophageal
acid exposure at their 3-year follow-up
Fig. 4 Effect of blinded turn-off and turn-on on esophageal acid
exposure. Esophageal acid exposure increased on blinded turn-off
before the 2-year pH study and then improved after blinded turn-on at
2 years, as measured at their 3-year follow-up. EST electrical
stimulation therapy
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3/4th of the patients, mostly partial responders, evaluated at
3-year follow-up on LES stimulation therapy had normal-
ized their esophageal acid exposure, while the remaining
1/4th had improved (39–48 %) but not normalized eso-
phageal acid exposure. This important observation high-
lights the durability of acid exposure control with LES
stimulation over time. Sustained long-term control of
esophageal acid exposure is essential for any effective
GERD therapy. This contrasts with the abnormal esopha-
geal pH values documented in 56 % of patients with
refractory heartburn on twice daily PPI, and in 30 % of
patients with typical GERD symptoms who were well
controlled on once daily PPI [15, 16]. In another study,
50 % of patients with GERD, who achieved complete
symptom control with PPI therapy, were found to have
abnormal esophageal exposure while on PPI [17].
In addition to the objective improvement in esophageal
acid exposure, there was also a significant and sustained
improvement in patient-centric outcomes of GERD
symptoms, both on and off PPI as well as acid suppression
medication use at 3 years on LES stimulation. Almost two-
thirds of the patients chose to undergo antireflux surgery
due to incomplete symptom control with medication, and
the rest were unwilling to take medications due to quality
of life, safety or cost concerns. The proportion of patients
and physicians concerned about long-term safety of high-
dose PPI, and the literature on this topic is growing,
resulting in an increasing number of patients and physi-
cians who desire an alternative to long-term PPI [18].
Dependence on daily PPI was eliminated in 80 % with
additional 20 % using PPI, albeit at a reduced dose.
Although elimination of any PPI use in all patients is the
most desirable outcome, a significant reduction in the
cumulative dose is also quite beneficial, as some observa-
tional studies showed that the adverse effect profile of PPI
is dose dependent [19].
Finally, the greatest advantage of electrical stimulation
is its safety profile, observed in other applications over the
years. Except for anticipated events typically seen after a
laparoscopic implant procedure, no other significant
adverse events have been reported in our patients. More
importantly, due to the minimal anatomical disruption with
the electrode implant procedure, the usual side effects of
dysphagia, gas bloat or diarrhea seen with traditional
antireflux surgery were not encountered in our patients [6].
An ongoing international multicenter trial has reported
comparable results in a more diverse patient population and
across multiple operators [20]. Thus far in our experience,
the safety profile of LES stimulation appears to be quite
superior to traditional antireflux surgery [6]. However,
continuous monitoring of any safety events in a larger
group of patients, treated across multiple practice settings
over a longer follow-up period, is required to conclusively
establish the safety of this therapy.
There are limitation of our study, primarily the small
number of patients and open-label study design. We
believe that the profound improvement in 24-h esophageal
acid exposure sustained over a 3-year period is highly
unlikely to be a placebo response [21]. Additionally, our
blinded turn-off and turn-on sub-study points to a causal
effect of LES stimulation on improvement in the esopha-
geal acid exposure. A larger experience in diverse group of
patients and operators is needed to validate our trial results
for a wider application of this procedure. Such data are
currently being collected in the international multicenter
trial and in routine clinical practice in an international
multicenter registry. A well-designed sham control trial
would be helpful in overcoming the limitations of an open-
label design.
Comparative effectiveness study against standard
antireflux surgery has been recently discussed [22, 23].
However, such a study is likely to be quite difficult, given
Fig. 5 Sustained improvement in GERD symptoms as measured by
the composite GERD-HRQL scores at 3-year follow-up. Data:
median, IQR. All patients reported clinically significant improvement
(C50 % improvement in the composite GERD-HRQL score) in
symptoms at 3 years compared to baseline off PPI and better
composite GERD-HRQL scores than baseline on PPI
Fig. 6 PPI medication use at baseline and at 3-year follow-up. Most
patients (73 %) were free from PPI dependence (dependence defined
as C50 % diary days with PPI use)
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issues of patient preference and generalizability of the
results to less stringent patient population and operators.
We believe that the LES stimulation therapy fills a ‘‘ther-
apy gap’’ or an ‘‘under-met need’’ between pharma-
cotherapy and traditional antireflux surgery, particularly
given its excellent safety profile. Additionally, due to the
lack of any negative effect on esophageal body or LES
motor function demonstrated on high-resolution manome-
try, LES stimulation therapy may be a desirable option in
specific patient populations such as those with severe
esophageal dysmotility including aperistalsis, post-my-
otomy GERD in patients with achalasia and in patients
with GERD following laparoscopic sleeve gastrectomy for
obesity. Early experience suggests that LES stimulation
maybe effective in the latter group of patients.
In conclusion, at 3-year follow-up LES stimulation
therapy effectively controls esophageal acid exposure and
eliminates GERD symptoms and the need for regular PPI
medications in majority of GERD patients that were at least
partial PPI responder. LES stimulation had no long-term
side effects and was associated with minimal adverse
events mainly restricted to the post-op period. We believe
that based on our long-term results and those being
reported from the international multicenter trial [20], LES
stimulation could be a therapeutic option for well-informed
and select patients with GERD who are seeking an alter-
native to current medical or surgical therapies for GERD.
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